Health

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Carlsbad, CA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a…

3 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…

3 months ago

24/7 Market News: Kraig Labs Offers Safer, Natural Alternative to Health Risks from Nylon and Polyester Clothing

DENVER, Sept. 26, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial…

3 months ago

Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025

September 26, 2025 New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with…

3 months ago

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

September 26, 2025 09:30 ET  | Source: Orion Oyj ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS26 September 2025…

3 months ago

Medicenna Announces Results of Annual Meeting of Shareholders

TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage…

3 months ago

Organogenesis Provides Update on Second Phase 3 ReNu Study

Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain…

3 months ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

September 25, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) --…

3 months ago

Sapu Nanos Sapu003 Advances to Human Clinical Testing – Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients

Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney,…

3 months ago

Range Impact Announces $550,000 Capital Raise

Cleveland, Ohio, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public…

3 months ago